Orakl Oncology
AIxBio engine combining patient-derived tumor biology, clinical data, and AI to predict cancer drug performance.
Website: https://www.orakl-oncology.com/
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | Orakl Oncology |
| Tagline | AIxBio engine combining patient-derived tumor biology, clinical data, and AI to predict cancer drug performance [Orakl Oncology] |
| Headquarters | Paris, France [TechCrunch, December 2024] |
| Founded | 2023 [TechCrunch, December 2024] |
| Stage | Series A [The Next Web, November 2026] |
| Business model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth profile | Venture Scale |
| Founding team | Corporate Spinout [TechCrunch, December 2024] |
| Funding label | $50M+ [The Next Web, November 2026] |
| Total disclosed funding | Approximately $50,000,000 [The Next Web, November 2026] |
Links
Public sources
- Website: https://www.orakl-oncology.com/
- LinkedIn: https://fr.linkedin.com/company/orakloncology
Executive Summary
PUBLIC Orakl Oncology is building a techbio platform for oncology drug development that combines patient-derived tumor models, clinical data, and AI to predict how cancer drugs will perform in patients, and it merits investor attention now because it has moved from a 2023 research spin-out to a reported $34 million Series A-backed commercial push with blue-chip pharma engagement already in view [TechCrunch, December 2024] [The Next Web, November 2026] [HIT Consultant, November 2026]. The company was launched in 2023 as a spin-out from Gustave Roussy, with coverage tying the platform to roughly a decade of underlying research, which matters because the technical claim rests less on a pure software layer than on proprietary biology-data generation linked to clinical context [BioSpace] [TechCrunch, December 2024].
Its product story is still best read as platform-first: Orakl says it grows patient-derived tumor organoids, tests drug candidates on them, and combines those results with medical records and other clinical information; the commercial surfaces described in public reporting are O-Predict, for forecasting patient response, and O-Validate, for selecting or validating patient populations and treatment hypotheses [TechCrunch, December 2024] [Orakl Oncology] [HLTH, November 2026]. That positioning is credible if the biology and data assets scale together, but the headline performance claims, including reported 90 percent predictive accuracy across more than 30 clinical trials, remain only partially corroborated in public sources and should be treated as promising rather than settled [EU-Startups, November 2026] [Artiverse] [Orakl Oncology].
The founding team appears well matched to the scientific ambition. Public sources identify Fanny Jaulin as co-founder and CEO, Gustave Ronteix as co-founder and CTO, and Diane-Laure Pagès as co-founder and COO, while external profiles and interviews point to backgrounds spanning cancer biology, computational work, and translational execution around Gustave Roussy [BioSpace] [Pulse 2.0, November 2026] [Ausha, 2026].
On financing, the clearest public record is a December 2024 Singular-led seed round of €11 million and a November 2026 Series A of $34 million co-led by Norrsken VC and Singular, with participation from InfraVia, Serena, Patient Autonome Fund, teampact.ventures, Plug and Play, Verve Ventures, Speedinvest, and HCVC; multiple outlets describe total disclosed funding at roughly $50 million [Drug Discovery World, 2024] [The Next Web, November 2026] [Tech Funding News, November 2026]. The business model is B2B, with pharma and biotech customers using the platform to inform target selection, asset evaluation, patient stratification, and clinical-trial decisions, and Sanofi is the one named pharmaceutical relationship in the public record, covering two agreements and four cancer assets [TechCrunch, December 2024] [European Biotechnology Magazine] [HIT Consultant, November 2026].
Over the next 12 to 18 months, the key watchpoints are whether Orakl can convert early platform interest into repeatable multi-year revenue, validate its predictive claims in broader third-party settings, and scale from its initial colorectal and pancreatic focus into additional indications such as lung and gastric cancer without diluting execution [BioSpace] [The Next Web, November 2026]. Public hiring signals across commercial, partnership, and technical roles also suggest a company shifting from research foundation to go-to-market buildout, which is usually the phase where platform coherence either strengthens or starts to fray [LinkedIn] [Branding Jobs] [freehire].
Lightly corroborated -- This section relies on named-publication reporting and company materials, with several core operational and performance claims only partially corroborated across public sources.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Corporate Spinout |
| Funding | $50M+ total disclosed |
How the Company Got Here
PUBLIC
Orakl Oncology presents as a recent French TechBio company built around a specific translational oncology claim, namely that patient-derived tumor biology can be combined with clinical data and machine learning to predict how cancer drugs will perform before or during development [Orakl Oncology] [Crunchbase]. Public company materials and its Crunchbase profile place the business in Paris, France, and date its founding to 2023 [Orakl Oncology] [Crunchbase]. The company also describes itself as an oncology-focused spin-out from Gustave Roussy, which is the central fact in the founding story because it implies the scientific base predates the corporate entity itself [Orakl Oncology].
The public record is still thin on legal-entity detail, but the operating outline is clearer. Orakl names Fanny Jaulin, Gustave Ronteix, and Diane-Laure Pagès as co-founders on its website, and Crunchbase lists the same founding year and Paris headquarters, which is enough to anchor the core company profile without stretching beyond the available filings-grade evidence [Orakl Oncology] [Crunchbase].
The milestone sequence is short but coherent. The company was founded in 2023, launched publicly around its early financing that year, and by late 2024 was presenting a defined platform and product architecture to pharmaceutical customers through offerings referred to publicly as O-Predict and O-Validate on its website [Orakl Oncology] [Crunchbase]. By the time of its later financing, Orakl was positioning itself less as a pure research spin-out and more as a commercial platform company serving oncology drug developers, although the underlying public-company record remains centered on its website and venture databases rather than statutory disclosures [Orakl Oncology] [Crunchbase].
Independently corroborated -- Confirmed by Orakl Oncology website and Crunchbase.
Product and Technology
MIXED
The product claim is straightforward even if the proof points remain uneven. Orakl says it grows patient-derived tumor models, tests drug candidates against them, and combines the resulting biological readouts with medical records and other clinical information to predict how a therapy may perform in patients [TechCrunch, December 2024] [Orakl Oncology] [The Next Web, November 2026]. Public coverage describes two planned product surfaces: O-Predict, aimed at forecasting patient response to a drug candidate, and O-Validate, aimed at validating treatment hypotheses or selecting patient populations [TechCrunch, December 2024]. The company and later trade coverage frame the broader platform as a decision tool for oncology drug developers across target selection, asset evaluation, patient stratification, and clinical trial design, but those workflow claims are still largely described in company-led or financing coverage rather than independent product reviews [Orakl Oncology] [HIT Consultant, November 2026].
The technical differentiator, if it holds up in commercial use, appears to be the pairing of wet-lab patient biology with a computational prediction layer rather than an AI-only discovery stack. Orakl and several financing articles describe a dataset built from tumor organoids, drug screening results, and genomic, transcriptomic, phenotypic, and longitudinal clinical data [Orakl Oncology] [HLTH, November 2026] [The Next Web, November 2026]. Reported performance claims are stronger than the underlying public evidence: the company cites 90% prospective prediction accuracy across more than 30 clinical trials, and secondary coverage repeats that figure, but the public material here does not include a peer-reviewed validation package or a verified demo that would let an outside reader test calibration, indication mix, or failure cases [Orakl Oncology] [EU-Startups, November 2026]. Hiring signals suggest the stack likely spans data science, AI engineering, computational biology, and organoid model development (inferred from job postings), which is consistent with the hybrid product narrative but does not by itself validate model performance in production [LinkedIn] [Branding Jobs].
Orakl's publicly announced scope is narrow enough to be credible. Early coverage tied the company to colorectal and pancreatic cancers, while 2026 reporting said Series A capital would support expansion into lung and gastric cancers; a separate report also said Orakl had signed two agreements with Sanofi covering four oncology assets, although target, modality, stage, and economics were not disclosed [BioSpace] [The Next Web, November 2026] [European Biotechnology Magazine]. That leaves the product story in a familiar TechBio position: the architecture is intelligible, the customer use case is legible, and the external evidence for repeatable predictive advantage is still developing.
Company-stated, unverified -- This section relies materially on company website claims and financing coverage, with partial corroboration from TechCrunch and trade publications but no independently verified demo or peer-reviewed validation in the provided sources.
Where the Demand Sits
PUBLIC
The market matters now because oncology drug development still destroys large amounts of capital in late-stage failure, and Orakl is positioned against that budget line rather than against a narrow point solution in discovery workflows [TechCrunch, December 2024] [The Next Web, November 2026].
The public record does not provide a named third-party TAM, SAM, or SOM specific to Orakl’s category, so the cleaner framing is functional rather than numeric. Orakl sells into oncology R&D decision-making for pharmaceutical and biotechnology companies, with its platform described as supporting target selection, asset evaluation, patient stratification, and clinical trial decisions [TechCrunch, December 2024] [HLTH, November 2026]. That places it at the intersection of several adjacent spend pools: preclinical translational models, biomarker and patient-selection tools, and clinical development analytics. The practical implication is that demand does not depend on a new budget being created from scratch if buyers can fund the product from existing translational or clinical-development programs [TechCrunch, December 2024] [HIT Consultant, November 2026].
The strongest tailwind in the source set is economic pressure from oncology attrition. Orakl and third-party coverage repeatedly anchor the pitch to predicting which cancer drugs will work in patients before or during clinical development, a claim aimed directly at the cost of failed trials and weak patient-selection decisions [TechCrunch, December 2024] [The Next Web, November 2026] [Tech Funding News, November 2026]. Public reporting also indicates early commercial interest from large pharma, with coverage stating that Orakl had a pipeline involving 18 of the world’s 20 largest pharmaceutical companies and was supporting or planning to support more than 10 active development programs, although those figures remain single-source or lightly corroborated and should be treated cautiously [Tech Funding News, November 2026] [HLTH, November 2026]. Even with that caveat, the direction of travel is clear: buyers appear willing to test tools that promise better translational accuracy between lab models and human outcomes.
The substitute market is broader than AI drug discovery alone. Orakl is also competing for budgets otherwise spent on contract lab services, organoid-based screening, translational oncology platforms, biomarker discovery programs, and internal clinical strategy teams using historical trial and real-world datasets [TechCrunch, December 2024] [HIT Consultant, November 2026]. Its differentiation, according to the cited coverage, rests on combining patient-derived tumor biology with clinical and computational data rather than offering only a software model or only a wet-lab assay [TechCrunch, December 2024] [The Next Web, November 2026]. That positioning can be attractive in procurement terms because it speaks to a complete decision workflow, but it also means the company must prove value across both experimental throughput and predictive performance.
Regulation and macro conditions are supportive in a narrow, practical sense. Drug developers face growing pressure to show clearer evidence for patient stratification, trial design, and translational relevance in oncology, especially as development costs remain elevated and capital has become more selective across venture-backed biotech and platform tooling [HLTH, November 2026] [The Next Web, November 2026]. Orakl’s reported expansion plans into the US and UK, and its agreements with Sanofi on four oncology assets, suggest the company is targeting geographies and counterparties where oncology development budgets remain concentrated, though the disclosed reporting does not provide financial terms or program-stage detail for those collaborations [European Biotechnology Magazine] [The Next Web, November 2026].
| Market frame | Public evidence | Read-through for Orakl |
|---|---|---|
| Oncology clinical-development decision tools | Orakl is described as helping forecast patient response and inform clinical-trial decisions for pharma and biotech buyers [TechCrunch, December 2024] [HLTH, November 2026] | Budget may come from existing clinical and translational R&D spend rather than a new software line item |
| Translational biology and organoid screening | Coverage describes patient-derived tumor models tested against drug candidates [TechCrunch, December 2024] [The Next Web, November 2026] | Supports a services-plus-platform motion, but raises execution demands in lab operations |
| AI and data layers for patient stratification | Reporting cites use of clinical data, medical records, and computational models to select populations and hypotheses [TechCrunch, December 2024] [HIT Consultant, November 2026] | Value case improves if the company can show better trial design or cohort selection than incumbent workflows |
The table shows a market best understood as converging budgets rather than a single clean category. That can help early adoption, because the company can attach to several existing pain points, but it also complicates benchmarking against one settled peer set.
Lightly corroborated -- Section rests on named-publisher reporting from TechCrunch, The Next Web, HLTH, HIT Consultant, Tech Funding News, and European Biotechnology Magazine, but no named third-party market sizing report was provided and several demand indicators remain single-source or partially corroborated.
Competitive Landscape
MIXED Orakl Oncology is competing less against a single named startup peer than against three established ways oncology programs are de-risked today: internal pharma translational teams, contract research workflows built around organoids or preclinical screening, and software-led drug development platforms that try to infer trial outcomes from data without owning the wet-lab layer [TechCrunch, December 2024] [The Next Web, November 2026] [HIT Consultant, November 2026].
The map matters because Orakl sits at an awkward but potentially valuable intersection. Large pharmaceutical companies already run internal biology, biomarker, and translational medicine groups, which means Orakl is not selling into a blank space, it is asking buyers to trust an external prediction engine on decisions that affect trial design and asset prioritization [TechCrunch, December 2024] [HLTH, November 2026]. Adjacent substitutes also include CRO-style preclinical testing and broader AI drug discovery vendors, but Orakl's public pitch is narrower and more concrete: build patient-derived tumor models, test drugs on them, and combine those outputs with clinical records and multi-omic data to forecast how therapies may perform in patients [Orakl Oncology] [The Next Web, November 2026].
That positioning gives the company a defensible edge if the underlying dataset compounds. Public materials repeatedly point to patient-derived organoids linked to genomic, transcriptomic, phenotypic, and longitudinal clinical data, with an initial focus on colorectal and pancreatic cancers, and a spin-out origin from Gustave Roussy [Orakl Oncology] [BioSpace] [TechCrunch, December 2024]. In practical terms, the strongest barrier appears to be data generation rather than model architecture alone: if Orakl can keep adding matched biology-plus-outcomes data through pharma programs and cancer-center relationships, the asset becomes harder to replicate quickly, though still perishable if customers treat the company as a service provider rather than a system of record for translational decisions [HLTH, November 2026] [Tech Funding News, November 2026].
The exposure is just as clear. Orakl does not appear, from public evidence, to own a broad distribution channel, a regulatory standard, or a category-defining platform with named customer references beyond Sanofi, so buyer trust may hinge on a small number of proof points and on whether prospective accuracy claims hold up under external scrutiny [European Biotechnology Magazine] [EU-Startups, 2026] [The Next Web, November 2026]. That leaves the company vulnerable to two classes of competitor even if they are unnamed in the sourced record: first, large pharma teams that prefer to keep sensitive translational work in-house; second, better-capitalized techbio platforms that can bundle discovery software, biomarker analysis, and clinical decision support into an existing commercial relationship [TechCrunch, December 2024] [HIT Consultant, November 2026].
Over the next 18 months, the most plausible scenario is a contest between data density and procurement friction. Orakl is the likely winner if its Sanofi work converts into additional named, multi-program pharma relationships and if its reported expansion into more than 10 active development programs produces visible referenceability across tumor types [European Biotechnology Magazine] [HLTH, November 2026]. Orakl is the likely loser if internal pharma translational teams remain the default buyer choice and if the company cannot move its current positioning from a promising predictive layer into a repeatable budget line inside oncology R&D organizations [Tech Funding News, November 2026] [TechCrunch, December 2024].
Opportunity
PUBLIC
The prize here is not a better oncology software dashboard, it is a credible shot at becoming part of the decision stack large drugmakers use to decide which cancer programs advance into expensive trials, and which do not [TechCrunch, December 2024] [The Next Web, November 2026].
The headline opportunity rests on a simple but consequential claim: if Orakl can consistently show that patient-derived tumor models plus clinical data improve prediction of drug response, it could become a high-value translational layer between preclinical work and clinical development [TechCrunch, December 2024] [HIT Consultant, November 2026]. That outcome is reachable, not merely aspirational, because the public record already shows three ingredients that usually matter in this category. First, the company was spun out of Gustave Roussy in 2023, which gives it an origin in a major cancer research institution rather than a generic software launch [BioSpace] [TechCrunch, December 2024]. Second, Orakl has moved beyond pure platform description into named pharma engagement, with Sanofi agreements covering four oncology assets reported in 2026 [European Biotechnology Magazine] [The Next Web, November 2026]. Third, the company has raised meaningful capital, including an €11 million seed round led by Singular in December 2024 and a $34 million Series A announced in November 2026, giving it the balance sheet to generate more wet-lab and clinical evidence before the market fully decides whether this model belongs in standard development workflows [Drug Discovery World, 2024] [The Next Web, November 2026].
The most credible upside paths are not all the same, and the distinction matters because each depends on a different proof point.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Become a translational decision layer for big pharma | Orakl wins repeat program work from large pharmaceutical companies and becomes a standing partner for patient stratification, asset triage, and trial design in oncology | Early collaborations convert into multi-year relationships, with Sanofi as the first visible reference account [HIT Consultant, November 2026] [European Biotechnology Magazine] | Public reporting says Orakl's platform is aimed at pharma and biotech buyers, and coverage in 2026 described a commercial pipeline involving 18 of the world's 20 largest pharmaceutical companies, though those names were not disclosed [TechCrunch, December 2024] [Tech Funding News, November 2026] |
| Build the evidence backbone for virtual patient cohorts | Orakl's organoid-plus-clinical-data engine becomes a trusted way to simulate likely trial outcomes before expensive enrollment decisions are made | More prospective validation across clinical programs, especially if the reported prediction accuracy continues to hold in external settings [EU-Startups, 2026] [HLTH, November 2026] | Multiple outlets reported that Orakl uses organoids, multi-omic data, and longitudinal clinical records to forecast treatment response, which is the right architecture for a virtual-cohort product if it proves reproducible at scale [HLTH, November 2026] [HIT Consultant, November 2026] |
| Expand from flagship indications into an oncology platform company | Orakl starts in colorectal and pancreatic cancer, then broadens into lung and gastric cancer and eventually supports a wider set of solid tumor programs | Successful deployment of Series A capital into higher lab throughput and new disease coverage [BioSpace] [The Next Web, November 2026] | The company has already stated an initial focus on colorectal and pancreatic cancers, and 2026 coverage tied new funding to expansion into lung and gastric cancers plus a fivefold increase in lab data generation [BioSpace] [The Next Web, November 2026] |
The compounding dynamic, if it appears, would come from a loop that is more biological than purely algorithmic. Each pharma program can add experimental response data from patient-derived tumor models, linked with clinical and molecular context, which in turn can make later predictions more useful for adjacent assets and cancer subtypes [Orakl Oncology] [HLTH, November 2026]. The public evidence suggests the first turns of that wheel may already be starting: Orakl has described a dataset built from tumor organoids enriched with genomic, transcriptomic, phenotypic, and longitudinal clinical information, and outside coverage reports both active pharma programs and negotiations with cancer centers that could broaden sample access over time [Orakl Oncology] [Tech Funding News, November 2026]. If that is borne out in practice, the moat is less about the model layer alone and more about the growing link between proprietary wet-lab outputs, disease-specific clinical histories, and embedded commercial relationships.
The size of the win is easiest to think about in strategic value terms rather than near-term revenue multiples. Public sources provided for this report do not include a named market-size study or a directly comparable public peer with a clean like-for-like valuation benchmark, so any valuation framing has to stay conditional. On a scenario basis, not a forecast, if Orakl became a standard translational platform for multiple top-tier oncology drug developers, the business could plausibly support an outcome measured in the low single-digit billions of dollars, because it would sit close to trial go or no-go decisions where even small improvements in prediction accuracy can affect very large R&D budgets [TechCrunch, December 2024] [The Next Web, November 2026]. That is still a demanding path. It requires evidence that the platform's reported predictive performance generalizes beyond early case studies and that pharma customers treat Orakl as operational infrastructure rather than an exploratory research vendor [EU-Startups, 2026] [HIT Consultant, November 2026].
Lightly corroborated -- Built mainly from TechCrunch, The Next Web, HIT Consultant, HLTH, BioSpace, Drug Discovery World, and company materials; several key upside claims, including broad pipeline breadth and predictive accuracy, remain only partially corroborated or company-linked.
Sources
Public sources
[Orakl Oncology] Orakl Oncology | https://www.orakl-oncology.com/
[TechCrunch, December 2024] Orakl Oncology combines data and biology to bring new drugs to cancer patients | https://techcrunch.com/2024/12/03/orakl-oncology-combines-data-and-biology-to-bring-new-drugs-to-cancer-patients/
[The Next Web, November 2026] Orakl Oncology raises $34M to predict cancer drug results with AI | https://thenextweb.com/news/orakl-oncology-34m-series-a-ai-cancer-drug-prediction
[HIT Consultant, November 2026] Orakl Oncology Raises $34 Million to Scale Virtual Cancer Patient Cohorts | https://hitconsultant.net/2026/11/12/orakl-oncology-raises-34-million-series-a-predict-cancer-clinical-trial-outcomes/
[BioSpace] Orakl Oncology raises €3 million to develop its techbio platform for precision oncology | https://www.biospace.com/orakl-oncology-raises-eur3-million-to-develop-its-techbio-platform-for-precision-oncology
[Ausha, 2026] #48 - Manager en s'appuyant sur ses forces - Fanny Jaulin - Orakl Oncology - CEO | Les Infaillibles - le podcast des managers qui se racontent avec authenticité pour un management qui allie performance et bienveillance | https://podcast.ausha.co/les-infaillibles/48-manager-en-s-appuyant-sur-ses-forces-fanny-jaulin-orakl-oncology-ceo
[Pulse 2.0, November 2026] Orakl Oncology: $34 Million Series A Funding Co-Led By Norrsken VC And Singular To Expand AI-Powered Cancer Drug Discovery | https://pulse2.com/orakl-oncology-34-million-series-a-funding-co-led-by-norrsken-vc-and-singular-to-expand-ai-powered-cancer-drug-discovery/
[Drug Discovery World, 2024] €11m supports launch of AI-powered drug development platform | https://www.ddw-online.com/11m-supports-launch-of-ai-powered-drug-development-platform-23729-202412/
[Tech Funding News, November 2026] Paris-based Orakl Oncology scoops $34M for AI cancer drug prediction | https://techfundingnews.com/paris-based-orakl-oncology-scoops-34m-for-ai-cancer-drug-prediction/
[European Biotechnology Magazine] Orakl takes on four Sanofi cancer assets | https://european-biotechnology.com/up-to-date/latest-news/news/orakl-takes-on-four-sanofi-cancer-assets.html
[LinkedIn] Orakl Oncology | LinkedIn | https://fr.linkedin.com/company/orakloncology
[Crunchbase] Orakl Oncology - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/orakl-oncology
[HLTH, November 2026] Orakl Oncology Raises $34M to Expand AI-Powered Cancer Clinical Trial Prediction Platform | https://hlth.com/insights/news/orakl-oncology-raises-34m-to-expand-ai-powered-cancer-clinical-trial-prediction-platform
[Branding Jobs] Communications, Brand & Events Lead at Orakl Oncology | https://www.branding-jobs.com/jobs/communications-brand-events-lead-ad7ea18e
Articles about Orakl Oncology
- A Spin-Out From Gustave Roussy Tests Four Sanofi Drugs in Silicon — The Paris-based spin-out from Europe's leading cancer center is betting its AIxBio engine can de-risk oncology drug development.